ICN to Expand Use of Anti-Wrinkle Laser

ICN Pharmaceuticals Inc. said Monday that the U.S. Food and Drug Administration approved a wider use of the company’s NLite laser system to include treatment of wrinkles in general.

ICN, based in Costa Mesa, had received FDA clearance in August 2000 to market NLite only for treating wrinkles around the eyes.

The non-cutting laser system uses laser light to stimulate the body’s own collagen layer to replenish itself. The procedure typically takes about 20 minutes in a doctor’s office and does not require anesthesia or post-operative care.

The stock closed at $29.75, down 39 cents a share, on the NYSE.